| O2⋅− and H2O2-mediated disruption of Fe metabolism causes the differential susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate JD Schoenfeld, ZA Sibenaller, KA Mapuskar, BA Wagner, ... Cancer cell 31 (4), 487-500. e8, 2017 | 479 | 2017 |
| Radioresistance in Glioblastoma and the Development of Radiosensitizers MY Ali, CR Oliva, ASM Noman, BG Allen, PC Goswami, Y Zakharia, ... Cancers 12 (9), 2511, 2020 | 133 | 2020 |
| Improved survival for extremity soft tissue sarcoma treated in high‐volume facilities T Abarca, Y Gao, V Monga, MR Tanas, MM Milhem, BJ Miller Journal of surgical oncology 117 (7), 1479-1486, 2018 | 76 | 2018 |
| Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations PK Brastianos, EL Twohy, ER Gerstner, TJ Kaufmann, AJ Iafrate, ... Journal of clinical oncology 41 (3), 618-628, 2023 | 74* | 2023 |
| First-in-human phase I clinical trial of pharmacologic ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma BG Allen, KL Bodeker, MC Smith, V Monga, S Sandhu, R Hohl, T Carlisle, ... Clinical Cancer Research 25 (22), 6590-6597, 2019 | 70 | 2019 |
| Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial MI de la Fuente, H Colman, M Rosenthal, BA Van Tine, D Levacic, ... Neuro-oncology 25 (1), 146-156, 2023 | 66 | 2023 |
| Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models JD Schoenfeld, ZA Sibenaller, KA Mapuskar, MD Bradley, BA Wagner, ... Redox biology 14, 417-422, 2018 | 62 | 2018 |
| Radiology gets chatty: the ChatGPT saga unfolds H Grewal, G Dhillon, V Monga, P Sharma, VS Buddhavarapu, G Sidhu, ... Cureus 15 (6), 2023 | 57 | 2023 |
| Radiomics-based differentiation between glioblastoma and primary central nervous system lymphoma: a comparison of diagnostic performance across different MRI sequences and … G Bathla, S Priya, Y Liu, C Ward, NH Le, N Soni, RP Maheshwarappa, ... European radiology 31 (11), 8703-8713, 2021 | 48 | 2021 |
| A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas V Monga, KM Skubitz, S Maliske, SL Mott, H Dietz, AC Hirbe, BA Van Tine, ... Cancers 12 (7), 1873, 2020 | 45 | 2020 |
| Ipilimumab: from preclinical development to future clinical perspectives in melanoma P Letendre, V Monga, M Milhem, Y Zakharia Future Oncology 13 (7), 625-636, 2016 | 43 | 2016 |
| CDKs in sarcoma: mediators of disease and emerging therapeutic targets JL Kohlmeyer, DJ Gordon, MR Tanas, V Monga, RD Dodd, DE Quelle International journal of molecular sciences 21 (8), 3018, 2020 | 40 | 2020 |
| Mitochondrial superoxide increases age-associated susceptibility of human dermal fibroblasts to radiation and chemotherapy KA Mapuskar, KH Flippo, JD Schoenfeld, DP Riley, S Strack, TA Hejleh, ... Cancer research 77 (18), 5054-5067, 2017 | 39 | 2017 |
| Machine learning based differentiation of glioblastoma from brain metastasis using MRI derived radiomics S Priya, Y Liu, C Ward, NH Le, N Soni, R Pillenahalli Maheshwarappa, ... Scientific reports 11 (1), 10478, 2021 | 37 | 2021 |
| Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study Y Zakharia, V Monga, U Swami, AD Bossler, M Freesmeier, M Frees, ... Oncotarget 8 (51), 89182, 2017 | 36 | 2017 |
| Turning ‘Cold’tumors ‘Hot’: immunotherapies in sarcoma J Rytlewski, MM Milhem, V Monga Annals of translational medicine 9 (12), 2021 | 32 | 2021 |
| Non-conventional treatments for conventional chondrosarcoma V Monga, H Mani, A Hirbe, M Milhem Cancers 12 (7), 1962, 2020 | 32 | 2020 |
| Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer M Furqan, T Abu-Hejleh, LM Stephens, SM Hartwig, SL Mott, CF Pulliam, ... Redox biology 53, 102318, 2022 | 27 | 2022 |
| Catalase overexpression drives an aggressive phenotype in glioblastoma S Flor, CR Oliva, MY Ali, KL Coleman, JD Greenlee, KA Jones, V Monga, ... Antioxidants 10 (12), 1988, 2021 | 26 | 2021 |
| A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine. MI De La Fuente, H Colman, M Rosenthal, BA Van Tine, D Levaci, ... Journal of clinical oncology 38 (15_suppl), 2505-2505, 2020 | 26 | 2020 |
Douglas SpitzProfessor of Radiation Oncology, University of Iowa確認したメール アドレス: uiowa.edu